BMS's Yervoy misses in prostate cancer

Bristol-Myers Squibb Co. (NYSE:BMY) said IV Yervoy ipilimumab following single-dose radiotherapy missed the primary endpoint of improving median overall survival (OS) vs. placebo following single-dose radiotherapy in the Phase III CA184-043 trial to treat metastatic castration-resistant prostate cancer (CRPC) (11.2 vs. 10 months, p=0.053). Yervoy led to a one-year OS rate of 47% vs. 40% for placebo and a two-year OS rate of 26% vs. 15% for placebo. Bristol-Myers plans to present the data, including detailed progression-free survival (PFS) data, at the European Cancer Congress this month. ...